Skip to main content
Christoph Correll, MD, Psychiatry, Glen Oaks, NY

ChristophUlrichCorrellMD

Psychiatry • Glen Oaks, NY

Child & Adolescent Psychiatry

Medical Director, Recognition and Prevention (RAP) Program, Department of Psychiatry, The Zucker Hillside Hospital Investigator, Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research Professor, Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine

Join to view full profile

Dr. Correll is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Correll's full profile

Already have an account?

  • Office

    The Zucker Hillside Hospital Dept of Psych
    75 59 263RD Street
    Glen Oaks, NY 11004
    Phone+1 718-470-4812

Education & Training

  • Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside Hospital
    Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalFellowship, Child and Adolescent Psychiatry, 2001 - 2003
  • Free Univ Berlin- Fac Med
    Free Univ Berlin- Fac MedClass of 1993
  • Long Island Jewish Medical Center
    Long Island Jewish Medical CenterResidency, Psychiatry

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2013 - 2026
  • American Board of Psychiatry and Neurology Psychiatry
  • American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association Between Cardiovascular Risk Factors and Cognitive Impairment in People with Schizophrenia  
    Christoph Correll, MD, JAMA Psychiatry
  • Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared with Management as Usual for Youth with Common Mental Health Problems  
    Christoph Correll, MD, JAMA Psychiatry
  • Impact of Comprehensive Treatment for First Episode Psychosis on Substance Use Outcomes: A Randomized Controlled Trial  
    Corinne Cather, Robert Rosenheck, Christoph U Correll, Psychiatry Research

Authored Content

  • Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
  • Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
  • Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
  • Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
  • Join now to see all

Press Mentions

  • A Lines of Therapy Analysis Found That Use of UZEDY as a First-Line Treatment Option Was at 12%. However, Patients Prescribed UZEDY Had Most Commonly Received Oral Second-Generation Antipsychotics as Their Initial Therapy
    A Lines of Therapy Analysis Found That Use of UZEDY as a First-Line Treatment Option Was at 12%. However, Patients Prescribed UZEDY Had Most Commonly Received Oral Second-Generation Antipsychotics as Their Initial TherapyNovember 1st, 2024
  • New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (Risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
    New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (Risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)September 21st, 2024
  • Long-Acting Subcutaneous Olanzapine Effective in Schizophrenia Trial
    Long-Acting Subcutaneous Olanzapine Effective in Schizophrenia TrialMay 8th, 2024
  • Join now to see all

Grant Support

  • Project 4 AcisrNational Institute Of Mental Health2010–2012
  • Project 1 AcisrNational Institute Of Mental Health2010–2012
  • Adverse Events Unit (Research Methods Core)National Institute Of Mental Health2010–2012
  • 3/3-Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Institute Of Mental Health2008–2011
  • Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Center For Research Resources2010
  • Factors For Metabolic Abnormalities In Children With Psychiatric DisordersNational Center For Research Resources2010
  • Biological And Genetic Risk Factors For Weight GAIN And Metabolic AbnormalitiesNational Center For Research Resources2007–2008
  • Biological &Genetic Risk Factors For Anti-Psychotic Induced Weight GAIN &MeNational Center For Research Resources2005–2006
  • Treating Refractory Childhood SchizophreniaNational Institute Of Mental Health2005

Dr. Christoph Correll, Dr. Christoph Correll, MD, Dr. C Correll, Dr. Christoph Ulrich Correll